China's new commercial insurance model could broaden access to Alzheimer's drugs

FierceBiotechWhy Execution Excellence Now Defines Biopharma Winners

FierceBiotechHow integrated strategy is reshaping biopharma growth

FierceBiotechBiotech value creation at an inflection point

FierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression

PharmaVoice3 potential takeover targets in obesity

FierceBiotechHow Unlearn is building a scientific intelligence layer for clinical development

FierceBiotechHow AI is reshaping biopharma decision-making

FierceBiotechBiopharma IPOs: Timing, capital and staying flexible

Roche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Endpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Endpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

Endpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B